Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematologic Neoplasms | 29 | 2023 | 1831 | 5.980 |
Why?
|
Myelodysplastic Syndromes | 23 | 2023 | 1352 | 5.280 |
Why?
|
Terminal Care | 12 | 2023 | 1694 | 2.190 |
Why?
|
Geriatric Assessment | 11 | 2023 | 1372 | 1.790 |
Why?
|
Neoplasms | 26 | 2024 | 21672 | 1.720 |
Why?
|
Hospice Care | 10 | 2023 | 672 | 1.680 |
Why?
|
Anemia | 5 | 2023 | 1504 | 1.470 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 11 | 2023 | 1378 | 1.450 |
Why?
|
Leukemia, Myeloid, Acute | 12 | 2023 | 3523 | 1.350 |
Why?
|
Health Care Rationing | 3 | 2021 | 437 | 1.330 |
Why?
|
Antineoplastic Agents | 17 | 2022 | 13668 | 1.100 |
Why?
|
Ethics Consultation | 2 | 2023 | 52 | 1.080 |
Why?
|
Hematopoietic Stem Cell Transplantation | 11 | 2023 | 5442 | 1.060 |
Why?
|
Quality of Life | 21 | 2023 | 12805 | 1.060 |
Why?
|
Bone Marrow Examination | 3 | 2016 | 157 | 1.050 |
Why?
|
Leukemia | 2 | 2024 | 1508 | 1.000 |
Why?
|
Myelodysplastic-Myeloproliferative Diseases | 1 | 2023 | 13 | 0.930 |
Why?
|
Medical Oncology | 10 | 2023 | 2265 | 0.910 |
Why?
|
Bone Marrow Cells | 3 | 2016 | 2513 | 0.840 |
Why?
|
Artificial Intelligence | 3 | 2024 | 2213 | 0.800 |
Why?
|
Marketing of Health Services | 2 | 2014 | 153 | 0.770 |
Why?
|
Cancer Care Facilities | 4 | 2021 | 402 | 0.730 |
Why?
|
Multiple Myeloma | 8 | 2023 | 5180 | 0.730 |
Why?
|
Aged | 67 | 2023 | 163253 | 0.690 |
Why?
|
Blood Transfusion | 3 | 2020 | 1296 | 0.670 |
Why?
|
Specimen Handling | 2 | 2014 | 694 | 0.660 |
Why?
|
Quality of Health Care | 5 | 2018 | 4371 | 0.660 |
Why?
|
Resource Allocation | 1 | 2021 | 341 | 0.660 |
Why?
|
Hepatitis B | 1 | 2024 | 695 | 0.650 |
Why?
|
Awareness | 2 | 2015 | 640 | 0.640 |
Why?
|
Humans | 135 | 2024 | 744220 | 0.640 |
Why?
|
State Government | 1 | 2021 | 372 | 0.620 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 5 | 2014 | 694 | 0.620 |
Why?
|
Hematology | 5 | 2020 | 221 | 0.620 |
Why?
|
Aged, 80 and over | 35 | 2022 | 57768 | 0.580 |
Why?
|
Standard of Care | 1 | 2021 | 564 | 0.580 |
Why?
|
Hematinics | 3 | 2016 | 281 | 0.580 |
Why?
|
Salaries and Fringe Benefits | 1 | 2019 | 264 | 0.570 |
Why?
|
Erythrocyte Transfusion | 1 | 2021 | 565 | 0.560 |
Why?
|
Lymphoma, Mantle-Cell | 3 | 2015 | 233 | 0.550 |
Why?
|
Hemoglobins | 2 | 2020 | 1533 | 0.550 |
Why?
|
Radiation Oncology | 1 | 2022 | 555 | 0.550 |
Why?
|
Drug Industry | 3 | 2016 | 745 | 0.550 |
Why?
|
Cause of Death | 2 | 2017 | 3584 | 0.540 |
Why?
|
Disease Management | 4 | 2020 | 2458 | 0.540 |
Why?
|
Patient Selection | 4 | 2020 | 4216 | 0.530 |
Why?
|
SEER Program | 7 | 2018 | 1508 | 0.530 |
Why?
|
Drug Substitution | 1 | 2018 | 281 | 0.520 |
Why?
|
Frail Elderly | 6 | 2023 | 693 | 0.490 |
Why?
|
Vincristine | 5 | 2022 | 1036 | 0.490 |
Why?
|
Climate Change | 1 | 2020 | 418 | 0.490 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 7281 | 0.480 |
Why?
|
Search Engine | 1 | 2015 | 144 | 0.480 |
Why?
|
Referral and Consultation | 5 | 2022 | 3528 | 0.460 |
Why?
|
Environmental Monitoring | 1 | 2020 | 1414 | 0.460 |
Why?
|
Hospices | 3 | 2023 | 265 | 0.460 |
Why?
|
Male | 70 | 2024 | 350027 | 0.450 |
Why?
|
Comorbidity | 8 | 2021 | 10387 | 0.450 |
Why?
|
Drugs, Generic | 1 | 2018 | 422 | 0.450 |
Why?
|
Glucaric Acid | 1 | 2012 | 10 | 0.440 |
Why?
|
United States | 32 | 2023 | 69867 | 0.440 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2018 | 3923 | 0.440 |
Why?
|
Iron-Dextran Complex | 1 | 2012 | 14 | 0.440 |
Why?
|
Perception | 4 | 2018 | 1198 | 0.440 |
Why?
|
Consumer Health Information | 1 | 2015 | 211 | 0.430 |
Why?
|
Severity of Illness Index | 4 | 2020 | 15538 | 0.430 |
Why?
|
Female | 73 | 2023 | 380197 | 0.430 |
Why?
|
Economics, Pharmaceutical | 1 | 2012 | 87 | 0.420 |
Why?
|
Medicare | 9 | 2023 | 6566 | 0.420 |
Why?
|
Lymphoma | 1 | 2021 | 1873 | 0.420 |
Why?
|
Bone Marrow Transplantation | 1 | 2019 | 2763 | 0.380 |
Why?
|
Middle Aged | 50 | 2022 | 213367 | 0.370 |
Why?
|
Ferric Compounds | 1 | 2012 | 374 | 0.370 |
Why?
|
Databases, Factual | 3 | 2016 | 7730 | 0.360 |
Why?
|
Palliative Care | 5 | 2021 | 3490 | 0.360 |
Why?
|
Patient Preference | 4 | 2019 | 887 | 0.340 |
Why?
|
Quality Indicators, Health Care | 2 | 2016 | 1831 | 0.330 |
Why?
|
Socioeconomic Factors | 5 | 2019 | 7784 | 0.330 |
Why?
|
Lymphoma, B-Cell | 1 | 2015 | 931 | 0.330 |
Why?
|
Aromatase Inhibitors | 1 | 2012 | 491 | 0.330 |
Why?
|
Population Surveillance | 3 | 2017 | 2616 | 0.320 |
Why?
|
Radiotherapy | 2 | 2017 | 1525 | 0.320 |
Why?
|
Symbolism | 1 | 2008 | 34 | 0.320 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2012 | 365 | 0.320 |
Why?
|
Survival Analysis | 9 | 2021 | 10250 | 0.320 |
Why?
|
Prognosis | 17 | 2023 | 29050 | 0.310 |
Why?
|
Cross-Sectional Studies | 10 | 2024 | 25043 | 0.310 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 3023 | 0.310 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 11493 | 0.300 |
Why?
|
Delayed Diagnosis | 1 | 2010 | 441 | 0.290 |
Why?
|
Lymphoproliferative Disorders | 1 | 2010 | 526 | 0.290 |
Why?
|
Drug Utilization | 1 | 2012 | 1183 | 0.280 |
Why?
|
Transplantation Conditioning | 1 | 2013 | 1598 | 0.270 |
Why?
|
Health Expenditures | 2 | 2018 | 2348 | 0.270 |
Why?
|
Biological Specimen Banks | 2 | 2022 | 712 | 0.260 |
Why?
|
Physicians, Primary Care | 1 | 2012 | 591 | 0.260 |
Why?
|
Physician-Patient Relations | 6 | 2019 | 3227 | 0.260 |
Why?
|
Blood Coagulation Disorders | 1 | 2008 | 337 | 0.260 |
Why?
|
Multivariate Analysis | 6 | 2019 | 12244 | 0.260 |
Why?
|
Janus Kinase 2 | 1 | 2008 | 528 | 0.250 |
Why?
|
Risk Assessment | 5 | 2019 | 23337 | 0.250 |
Why?
|
Survival Rate | 9 | 2022 | 12781 | 0.250 |
Why?
|
Information Dissemination | 4 | 2016 | 1100 | 0.250 |
Why?
|
Adult | 34 | 2023 | 214035 | 0.240 |
Why?
|
Cognition Disorders | 1 | 2018 | 4041 | 0.240 |
Why?
|
Positron-Emission Tomography | 3 | 2015 | 6274 | 0.240 |
Why?
|
Doxorubicin | 4 | 2014 | 2220 | 0.230 |
Why?
|
Lymphoma, Non-Hodgkin | 4 | 2013 | 1380 | 0.230 |
Why?
|
Bupropion | 1 | 2005 | 303 | 0.230 |
Why?
|
Self Report | 4 | 2018 | 3558 | 0.220 |
Why?
|
Central Nervous System Neoplasms | 1 | 2011 | 895 | 0.220 |
Why?
|
Drug Prescriptions | 1 | 2012 | 1637 | 0.220 |
Why?
|
Internet | 1 | 2015 | 3063 | 0.220 |
Why?
|
Health Services Accessibility | 2 | 2019 | 5138 | 0.220 |
Why?
|
Age Factors | 6 | 2021 | 18367 | 0.220 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2021 | 288 | 0.220 |
Why?
|
Ethics, Clinical | 1 | 2023 | 101 | 0.210 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2010 | 1596 | 0.210 |
Why?
|
Molecular Targeted Therapy | 2 | 2016 | 2727 | 0.210 |
Why?
|
Logistic Models | 7 | 2019 | 13409 | 0.210 |
Why?
|
Bilirubin | 1 | 2024 | 425 | 0.210 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 2005 | 503 | 0.210 |
Why?
|
Employment | 2 | 2019 | 1129 | 0.210 |
Why?
|
Prospective Studies | 13 | 2023 | 53280 | 0.210 |
Why?
|
Cohort Studies | 15 | 2016 | 40559 | 0.210 |
Why?
|
Electronic Health Records | 1 | 2018 | 4463 | 0.200 |
Why?
|
Disease Progression | 2 | 2017 | 13280 | 0.200 |
Why?
|
Marital Status | 1 | 2023 | 437 | 0.200 |
Why?
|
Patients | 3 | 2018 | 900 | 0.200 |
Why?
|
Health Care Costs | 1 | 2015 | 3209 | 0.200 |
Why?
|
Insurance, Health | 2 | 2013 | 2494 | 0.200 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 7908 | 0.190 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2022 | 97 | 0.190 |
Why?
|
Psychometrics | 3 | 2016 | 3002 | 0.190 |
Why?
|
Retrospective Studies | 17 | 2023 | 77426 | 0.190 |
Why?
|
Intensive Care Units | 3 | 2019 | 3680 | 0.190 |
Why?
|
Consensus | 2 | 2020 | 2958 | 0.190 |
Why?
|
Kaplan-Meier Estimate | 5 | 2019 | 6535 | 0.190 |
Why?
|
Treatment Outcome | 15 | 2020 | 63119 | 0.190 |
Why?
|
Anemia, Refractory, with Excess of Blasts | 2 | 2016 | 17 | 0.180 |
Why?
|
Patient Rights | 1 | 2021 | 126 | 0.180 |
Why?
|
Prednisone | 3 | 2014 | 1575 | 0.180 |
Why?
|
Risk Factors | 11 | 2023 | 72280 | 0.180 |
Why?
|
Hospital Bed Capacity | 1 | 2021 | 214 | 0.180 |
Why?
|
Polypharmacy | 1 | 2022 | 294 | 0.180 |
Why?
|
Hospitalization | 4 | 2022 | 10262 | 0.180 |
Why?
|
Thrombosis | 2 | 2016 | 2968 | 0.170 |
Why?
|
Activities of Daily Living | 2 | 2019 | 2420 | 0.170 |
Why?
|
Social Class | 3 | 2018 | 1999 | 0.170 |
Why?
|
Pharmacies | 1 | 2021 | 150 | 0.170 |
Why?
|
Social Justice | 1 | 2024 | 456 | 0.170 |
Why?
|
Lymphoma, Follicular | 2 | 2013 | 435 | 0.170 |
Why?
|
Patient Education as Topic | 1 | 2009 | 2277 | 0.170 |
Why?
|
Cyclophosphamide | 3 | 2014 | 2236 | 0.170 |
Why?
|
United States Food and Drug Administration | 3 | 2016 | 1583 | 0.170 |
Why?
|
Decision Making, Organizational | 1 | 2019 | 139 | 0.160 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2013 | 689 | 0.160 |
Why?
|
Cytogenetic Analysis | 1 | 2019 | 295 | 0.160 |
Why?
|
Diterpenes | 1 | 2019 | 173 | 0.160 |
Why?
|
Humanities | 1 | 2018 | 53 | 0.160 |
Why?
|
Prevalence | 3 | 2021 | 15226 | 0.160 |
Why?
|
Blood Donors | 1 | 2020 | 355 | 0.160 |
Why?
|
Proportional Hazards Models | 7 | 2023 | 12355 | 0.160 |
Why?
|
Models, Biological | 1 | 2014 | 9582 | 0.160 |
Why?
|
Health Priorities | 1 | 2021 | 380 | 0.150 |
Why?
|
HIV Infections | 1 | 2024 | 16718 | 0.150 |
Why?
|
Ambulatory Care Facilities | 1 | 2024 | 933 | 0.150 |
Why?
|
Attitude of Health Personnel | 3 | 2021 | 3842 | 0.150 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 3508 | 0.150 |
Why?
|
Delphi Technique | 1 | 2020 | 778 | 0.150 |
Why?
|
Health Care Surveys | 2 | 2017 | 2453 | 0.150 |
Why?
|
Tissue and Organ Harvesting | 1 | 2020 | 369 | 0.150 |
Why?
|
Myeloproliferative Disorders | 1 | 2023 | 605 | 0.150 |
Why?
|
Off-Label Use | 1 | 2018 | 169 | 0.140 |
Why?
|
Documentation | 1 | 2023 | 869 | 0.140 |
Why?
|
Odds Ratio | 4 | 2019 | 9849 | 0.140 |
Why?
|
Neoplasm Staging | 5 | 2020 | 11007 | 0.140 |
Why?
|
Communication | 3 | 2019 | 3749 | 0.140 |
Why?
|
Patient Participation | 1 | 2006 | 1457 | 0.140 |
Why?
|
Transplantation, Autologous | 3 | 2023 | 2124 | 0.140 |
Why?
|
Hand Strength | 1 | 2019 | 448 | 0.140 |
Why?
|
Transplantation, Homologous | 3 | 2020 | 4776 | 0.140 |
Why?
|
Mutation | 4 | 2022 | 29784 | 0.140 |
Why?
|
Uncertainty | 1 | 2021 | 734 | 0.140 |
Why?
|
Leukemia, Myeloid | 1 | 2019 | 705 | 0.140 |
Why?
|
Time Factors | 7 | 2016 | 40063 | 0.140 |
Why?
|
Periodicals as Topic | 1 | 2007 | 1432 | 0.130 |
Why?
|
Acute Disease | 2 | 2024 | 7148 | 0.130 |
Why?
|
Blue Cross Blue Shield Insurance Plans | 1 | 2016 | 94 | 0.130 |
Why?
|
Cytogenetics | 1 | 2016 | 203 | 0.130 |
Why?
|
Thrombocytopenia | 1 | 2023 | 1175 | 0.130 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2016 | 339 | 0.130 |
Why?
|
Azacitidine | 1 | 2016 | 347 | 0.120 |
Why?
|
Massachusetts | 3 | 2019 | 8663 | 0.120 |
Why?
|
Stem Cell Transplantation | 2 | 2013 | 1620 | 0.120 |
Why?
|
Diagnostic Self Evaluation | 1 | 2016 | 230 | 0.120 |
Why?
|
Vitamin K | 1 | 2016 | 295 | 0.120 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 20123 | 0.120 |
Why?
|
Focus Groups | 2 | 2020 | 1321 | 0.120 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1782 | 0.120 |
Why?
|
Sulfonamides | 1 | 2023 | 1940 | 0.120 |
Why?
|
Graft vs Host Disease | 2 | 2018 | 2957 | 0.120 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2019 | 1770 | 0.120 |
Why?
|
Minority Groups | 1 | 2021 | 1223 | 0.120 |
Why?
|
Patient Care Planning | 1 | 2019 | 921 | 0.120 |
Why?
|
Public Opinion | 1 | 2018 | 477 | 0.120 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2014 | 102 | 0.120 |
Why?
|
Critical Illness | 2 | 2017 | 2670 | 0.120 |
Why?
|
Gait | 1 | 2019 | 793 | 0.120 |
Why?
|
Economics | 1 | 2014 | 146 | 0.110 |
Why?
|
Communicable Disease Control | 1 | 2020 | 857 | 0.110 |
Why?
|
Morbidity | 1 | 2019 | 1769 | 0.110 |
Why?
|
Smoking Cessation | 1 | 2005 | 2071 | 0.110 |
Why?
|
Reference Values | 1 | 2020 | 4982 | 0.110 |
Why?
|
Patient Care | 1 | 2018 | 640 | 0.110 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2016 | 640 | 0.110 |
Why?
|
Data Collection | 3 | 2023 | 3340 | 0.110 |
Why?
|
Hodgkin Disease | 2 | 2011 | 1415 | 0.110 |
Why?
|
Follow-Up Studies | 8 | 2019 | 39045 | 0.100 |
Why?
|
Primary Health Care | 1 | 2008 | 4556 | 0.100 |
Why?
|
Sex Factors | 2 | 2016 | 10396 | 0.100 |
Why?
|
Pilot Projects | 2 | 2023 | 8321 | 0.100 |
Why?
|
Memory, Short-Term | 1 | 2018 | 975 | 0.100 |
Why?
|
Lymphoma, T-Cell | 1 | 2014 | 299 | 0.100 |
Why?
|
Sweating | 1 | 2012 | 123 | 0.100 |
Why?
|
Breast Neoplasms | 3 | 2019 | 20817 | 0.100 |
Why?
|
Melphalan | 1 | 2013 | 431 | 0.100 |
Why?
|
Benzamides | 2 | 2013 | 1378 | 0.100 |
Why?
|
Caregivers | 3 | 2023 | 2094 | 0.100 |
Why?
|
Blood Cell Count | 1 | 2012 | 402 | 0.100 |
Why?
|
Affect | 1 | 2019 | 1475 | 0.100 |
Why?
|
Mastectomy | 1 | 2019 | 1793 | 0.100 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2019 | 941 | 0.100 |
Why?
|
Sampling Studies | 1 | 2012 | 623 | 0.090 |
Why?
|
Costs and Cost Analysis | 1 | 2016 | 1682 | 0.090 |
Why?
|
Lymphatic Diseases | 1 | 2012 | 324 | 0.090 |
Why?
|
Drug Evaluation | 1 | 2011 | 637 | 0.090 |
Why?
|
Inappropriate Prescribing | 1 | 2012 | 202 | 0.090 |
Why?
|
Injections, Intravenous | 1 | 2012 | 1420 | 0.090 |
Why?
|
Cost Sharing | 1 | 2013 | 407 | 0.090 |
Why?
|
Income | 2 | 2016 | 1913 | 0.090 |
Why?
|
Needs Assessment | 1 | 2016 | 1147 | 0.090 |
Why?
|
Recurrence | 2 | 2012 | 8343 | 0.090 |
Why?
|
Professional Practice | 1 | 2012 | 326 | 0.090 |
Why?
|
Sunlight | 1 | 2011 | 325 | 0.090 |
Why?
|
Fatigue | 1 | 2017 | 1531 | 0.090 |
Why?
|
Classification | 1 | 2010 | 129 | 0.090 |
Why?
|
Health Personnel | 1 | 2023 | 3216 | 0.090 |
Why?
|
Drug Information Services | 1 | 2009 | 51 | 0.090 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1061 | 0.090 |
Why?
|
Insurance Coverage | 2 | 2018 | 1901 | 0.090 |
Why?
|
Hematopoietic Stem Cells | 1 | 2022 | 3385 | 0.090 |
Why?
|
Regression Analysis | 1 | 2019 | 6461 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 9960 | 0.080 |
Why?
|
Renal Dialysis | 1 | 2018 | 1787 | 0.080 |
Why?
|
Databases as Topic | 1 | 2010 | 475 | 0.080 |
Why?
|
Medicaid | 2 | 2013 | 2736 | 0.080 |
Why?
|
Developing Countries | 1 | 2021 | 2814 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1380 | 0.080 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2016 | 978 | 0.080 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1094 | 0.080 |
Why?
|
Analysis of Variance | 1 | 2017 | 6367 | 0.080 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4929 | 0.080 |
Why?
|
Intubation, Intratracheal | 1 | 2016 | 1357 | 0.080 |
Why?
|
Motivation | 1 | 2018 | 1971 | 0.080 |
Why?
|
Psycholinguistics | 1 | 2008 | 78 | 0.080 |
Why?
|
Health Status Indicators | 1 | 2013 | 969 | 0.080 |
Why?
|
Anticoagulants | 2 | 2016 | 4599 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1670 | 0.080 |
Why?
|
Depression | 3 | 2023 | 7767 | 0.080 |
Why?
|
Veterans | 1 | 2021 | 2519 | 0.080 |
Why?
|
Watchful Waiting | 1 | 2012 | 491 | 0.080 |
Why?
|
Patient Transfer | 1 | 2014 | 761 | 0.080 |
Why?
|
Iron | 1 | 2016 | 1774 | 0.080 |
Why?
|
Continuity of Patient Care | 1 | 2014 | 1049 | 0.070 |
Why?
|
International Cooperation | 1 | 2013 | 1421 | 0.070 |
Why?
|
Education, Medical | 1 | 2018 | 1721 | 0.070 |
Why?
|
Salvage Therapy | 1 | 2013 | 1275 | 0.070 |
Why?
|
Ultraviolet Rays | 1 | 2011 | 1060 | 0.070 |
Why?
|
Mass Media | 1 | 2009 | 305 | 0.070 |
Why?
|
Piperazines | 2 | 2013 | 2491 | 0.070 |
Why?
|
Patient-Centered Care | 1 | 2016 | 1438 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1660 | 0.070 |
Why?
|
Pathology, Clinical | 1 | 2010 | 368 | 0.070 |
Why?
|
Young Adult | 6 | 2019 | 56436 | 0.070 |
Why?
|
Drug Costs | 1 | 2013 | 1105 | 0.070 |
Why?
|
Hospital Mortality | 1 | 2019 | 5316 | 0.070 |
Why?
|
Poverty | 2 | 2014 | 2660 | 0.060 |
Why?
|
International Agencies | 2 | 2017 | 240 | 0.060 |
Why?
|
Pyrimidines | 2 | 2013 | 2940 | 0.060 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2012 | 1130 | 0.060 |
Why?
|
Patient Care Team | 1 | 2016 | 2529 | 0.060 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2013 | 2455 | 0.060 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2013 | 2017 | 0.060 |
Why?
|
World Health Organization | 1 | 2010 | 1318 | 0.060 |
Why?
|
Hospitals, General | 1 | 2008 | 749 | 0.060 |
Why?
|
Flow Cytometry | 2 | 2014 | 5974 | 0.060 |
Why?
|
Mental Disorders | 1 | 2023 | 6601 | 0.060 |
Why?
|
Cognition | 1 | 2021 | 6765 | 0.060 |
Why?
|
Biomedical Research | 1 | 2019 | 3311 | 0.060 |
Why?
|
Vitamins | 1 | 2011 | 1621 | 0.060 |
Why?
|
Aging | 2 | 2022 | 8661 | 0.050 |
Why?
|
Health Status | 1 | 2016 | 4034 | 0.050 |
Why?
|
Patient Satisfaction | 2 | 2019 | 3395 | 0.050 |
Why?
|
Ontario | 1 | 2023 | 383 | 0.050 |
Why?
|
Anxiety | 3 | 2023 | 4297 | 0.050 |
Why?
|
Registries | 4 | 2013 | 8090 | 0.050 |
Why?
|
DNA Methylation | 1 | 2016 | 4289 | 0.050 |
Why?
|
Medication Adherence | 1 | 2013 | 2062 | 0.050 |
Why?
|
Endoscopy | 1 | 2012 | 1784 | 0.050 |
Why?
|
Longitudinal Studies | 4 | 2019 | 13990 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5319 | 0.050 |
Why?
|
Critical Care | 1 | 2014 | 2644 | 0.050 |
Why?
|
Leukocyte Count | 1 | 2005 | 1584 | 0.050 |
Why?
|
Weight Loss | 1 | 2012 | 2622 | 0.050 |
Why?
|
Technology | 1 | 2023 | 304 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 2 | 2013 | 5529 | 0.050 |
Why?
|
Terminology as Topic | 1 | 2008 | 1548 | 0.050 |
Why?
|
Diagnosis, Differential | 2 | 2014 | 12961 | 0.050 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2022 | 209 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 8387 | 0.040 |
Why?
|
Boston | 2 | 2019 | 9311 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2016 | 19907 | 0.040 |
Why?
|
DNA Mutational Analysis | 1 | 2008 | 4188 | 0.040 |
Why?
|
Secondary Prevention | 1 | 2005 | 1531 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2013 | 5169 | 0.040 |
Why?
|
Physicians | 1 | 2016 | 4564 | 0.040 |
Why?
|
Adolescent | 5 | 2023 | 85759 | 0.040 |
Why?
|
Vitamin D | 1 | 2011 | 3222 | 0.040 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2019 | 314 | 0.040 |
Why?
|
Cytarabine | 1 | 2019 | 692 | 0.040 |
Why?
|
Anthracyclines | 1 | 2019 | 288 | 0.040 |
Why?
|
Breast Implantation | 1 | 2019 | 218 | 0.040 |
Why?
|
Dexamethasone | 1 | 2023 | 1948 | 0.030 |
Why?
|
Healthcare Disparities | 1 | 2011 | 3158 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2006 | 2759 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2013 | 9230 | 0.030 |
Why?
|
North America | 1 | 2018 | 1250 | 0.030 |
Why?
|
Enteropathy-Associated T-Cell Lymphoma | 1 | 2014 | 12 | 0.030 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2014 | 35 | 0.030 |
Why?
|
Body Mass Index | 2 | 2016 | 12718 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 173 | 0.030 |
Why?
|
Markov Chains | 1 | 2016 | 969 | 0.030 |
Why?
|
Algorithms | 1 | 2014 | 13885 | 0.030 |
Why?
|
Bone Marrow | 1 | 2023 | 2944 | 0.030 |
Why?
|
Neutrophils | 1 | 2005 | 3717 | 0.030 |
Why?
|
Bone Marrow Diseases | 1 | 2014 | 230 | 0.030 |
Why?
|
Anemia, Aplastic | 1 | 2014 | 226 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2002 | 2715 | 0.030 |
Why?
|
Quality Improvement | 2 | 2019 | 3746 | 0.030 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 169 | 0.030 |
Why?
|
Educational Status | 1 | 2019 | 2539 | 0.030 |
Why?
|
New England | 1 | 2014 | 1022 | 0.030 |
Why?
|
Health Services Research | 1 | 2019 | 1836 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2005 | 12035 | 0.020 |
Why?
|
Teaching | 1 | 2018 | 1174 | 0.020 |
Why?
|
Anxiety Disorders | 1 | 2022 | 2691 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2016 | 1683 | 0.020 |
Why?
|
Faculty, Medical | 1 | 2018 | 1181 | 0.020 |
Why?
|
Social Support | 1 | 2019 | 2117 | 0.020 |
Why?
|
Life Expectancy | 1 | 2016 | 1184 | 0.020 |
Why?
|
Insurance | 1 | 2011 | 111 | 0.020 |
Why?
|
Mammaplasty | 1 | 2019 | 1204 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2014 | 1880 | 0.020 |
Why?
|
Gene Expression | 1 | 2022 | 7799 | 0.020 |
Why?
|
Adaptation, Psychological | 1 | 2019 | 2576 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2020 | 3611 | 0.020 |
Why?
|
New York | 1 | 2011 | 886 | 0.020 |
Why?
|
Program Development | 1 | 2013 | 1315 | 0.020 |
Why?
|
California | 1 | 2011 | 1402 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2013 | 2539 | 0.020 |
Why?
|
Students, Medical | 1 | 2018 | 1862 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8628 | 0.020 |
Why?
|
Bone Diseases | 1 | 2009 | 416 | 0.020 |
Why?
|
Back Pain | 1 | 2009 | 545 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2022 | 10182 | 0.020 |
Why?
|
Cost of Illness | 1 | 2014 | 1859 | 0.020 |
Why?
|
Decision Making | 1 | 2018 | 3888 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5396 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2013 | 2050 | 0.010 |
Why?
|
Chronic Disease | 1 | 2018 | 9147 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 2942 | 0.010 |
Why?
|
Research Design | 1 | 2019 | 5987 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2013 | 6893 | 0.010 |
Why?
|
Observer Variation | 1 | 2008 | 2593 | 0.010 |
Why?
|
Inflammation | 1 | 2022 | 10634 | 0.010 |
Why?
|
Nurses | 1 | 2011 | 2461 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11368 | 0.010 |
Why?
|
Incidence | 1 | 2017 | 20945 | 0.010 |
Why?
|
Health Status Disparities | 1 | 2011 | 1797 | 0.010 |
Why?
|
Dietary Supplements | 1 | 2011 | 3297 | 0.010 |
Why?
|
Kidney Diseases | 1 | 2009 | 2147 | 0.010 |
Why?
|
Diet | 1 | 2011 | 7937 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2008 | 15070 | 0.010 |
Why?
|
Child, Preschool | 1 | 2014 | 40992 | 0.010 |
Why?
|
Child | 1 | 2014 | 77679 | 0.000 |
Why?
|